Author, as appears in the article.: Aparicio, J.; Terrasa, J.; Duran, I.; Germa-Lluch, J. R.; Girones, R.; Gonzalez-Billalabeitia, E.; Guma, J.; Maroto, P.; Pinto, A.; Garcia-del-Muro, X.;
Department: Medicina i Cirurgia
URV's Author/s: Gumà Padró, José
Keywords: Tumors Testicular cancer Term-follow-up Surgery Stage-i seminoma Risk Randomized-trial Prognostic-factors Phase-iii Lymph-node dissection Germ-cell tumor Chemotherapy Adjuvant treatment
Abstract: Testicular cancer represents the most common malignancy in males aged 15-34 years and is considered a model of curable neoplasm. Maintaining success, reducing treatment burden, and focusing on survivorship are then key objectives. Inguinal orchiectomy is the first recommended maneuver that has both diagnostic and therapeutic aims. Most patients are diagnosed with stage I disease (confined to the testicle). Close surveillance and selective, short-course adjuvant chemotherapy are accepted alternatives for these cases. In patients with more advanced disease (stages II and III), 3-4 courses of cisplatin-based chemotherapy (according to IGCCCG risk classification) followed by the judicious surgical removal of residual masses represent the cornerstone of therapy. Poor-risk patients and those failing a first-line therapy should be referred to specialized tertiary centers. Paclitaxel-based conventional chemotherapy and high-dose chemotherapy plus autologous hematopoietic support can cure a proportion of patients with relapsing or refractory disease.
Thematic Areas: Saúde coletiva Oncology Odontología Medicine (miscellaneous) Medicina veterinaria Medicina ii Medicina i Farmacia Engenharias ii Ciências biológicas ii Ciências biológicas i Cancer research Biotecnología
licence for use: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 1699048X
Author's mail: jose.guma@urv.cat
Author identifier: 0000-0001-7541-9832
Record's date: 2024-09-07
Papper version: info:eu-repo/semantics/publishedVersion
Link to the original source: https://link.springer.com/article/10.1007/s12094-016-1566-1
Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
Papper original source: Clinical & Translational Oncology. 18 (12): 1187-1196
APA: Aparicio, J.; Terrasa, J.; Duran, I.; Germa-Lluch, J. R.; Girones, R.; Gonzalez-Billalabeitia, E.; Guma, J.; Maroto, P.; Pinto, A.; Garcia-del-Muro, X (2016). SEOM clinical guidelines for the management of germ cell testicular cancer (2016). Clinical & Translational Oncology, 18(12), 1187-1196. DOI: 10.1007/s12094-016-1566-1
Article's DOI: 10.1007/s12094-016-1566-1
Entity: Universitat Rovira i Virgili
Journal publication year: 2016
Publication Type: Journal Publications